What did Jefferies say in the March 06, 2026 ATYR analyst rating update?

Jefferies on March 06, 2026 maintained a **Buy** on ATYR and noted a **low** probability of immediate EFZO‑FIT approval. The firm cited regulatory timing risk but kept a positive longer term view.

Does the note include an ATYR price target?

The StreetInsider summary did not list a new ATYR price target. Investors should check full analyst reports and company filings for any formal target updates.

How should investors interpret a maintained Buy for ATYR?

A maintained Buy means the analyst expects better returns versus peers over the next 12 months, but it still implies risk from regulatory timing and trial outcomes. Match any decision to your risk profile.

How does Meyka AI grade affect view of this ATYR analyst rating?

Meyka AI rates ATYR with a **grade of B**, which reflects benchmark, sector, growth, metrics, and analyst consensus. Use the grade with other data and not as sole investment guidance.

Analyst Ratings

Jefferies Maintains Buy on ATYR aTyr Pharma, Inc. March 2026

ByDanny Kontos March 7, 2026March 7, 2026

Jefferies maintained a Buy on aTyr Pharma, Inc. on March 06, 2026, updating the ATYR analyst rating and stressing regulatory risk around EFZO‑FIT. The firm reiterated Buy while saying immediate approval probability for EFZO‑FIT is low. Jefferies left the outlook intact despite that regulatory caution. This call followed public commentary published on StreetInsider and tracked in our coverage